Nov 7 (Reuters) - Italian drugmaker Recordati (RECI.MI) expects its 2023 results to land at the high-end of previously indicated ranges as it reported double-digit growth in revenue and net profit in the first nine months of the year on Tuesday.
MILAN, Feb 21 (Reuters) - Shares in Recordati (RECI.MI) fell as much as 4.3% on Tuesday after the Italian drug maker unveiled a cautious outlook for core profit margin in both 2023 and 2025 that came in just short of analyst expectations.
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today that multiple positive data sets highlighting ISTURISA were presented at the annual ENDO 2022 meeting in Atlanta, Georgia. The Phase III LINC 4 study demonstrates ISTURISA maintained normal mean urinary free cortisol (mUFC) long-term in patients with Cushing’s disease, the Phase III LINC 3 study found adrenal hormone levels changed during early treatment with ISTURISA while stabilizing during long-term treatment, and the ILLUSTRATE study showed patients treated with a prolonged titration interval tended to have greater persistence with therapy. ISTURISA is a cortisol synthesis inhibitor indicated in the United States for the treatment of adult patients with Cushing’s disease.
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 – 14, 2022. Recordati will be exhibiting at booth #821.
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 – 14, 2022. Recordati will be exhibiting at booth #122.
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announce today the publication of positive results from the Phase III LINC 4 study of ISTURISA in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce ISTURISA as an effective and well-tolerated oral therapy for patients with Cushing’s disease. ISTURISA is indicated in the United States for the treatment of adult patients with Cushing’s disease,2 a rare and debilitating condition of hypercortisolism that is caused by a pituitary adenoma.3
An Italian pharma company engineered a nearly $850 million buyout last week looking to expand its rare disease portfolio and further soak up parts of the US market, but questions remain over the drugs involved and when they could see patient uptake stateside.
Italian drugmaker Recordati has agreed on a price for six-year-old EUSA Pharma. The Milan-based firm will pay €750m ($845 million) for EUSA’s portfolio of drugs to treat rare cancers.
With Thursday’s nod from England’s drug-price watchdog, Givlaari will soon be provided through the National Health Service. The recommendation reverses (PDF) the National Institute for Health and Care Excellence's (NICE's) previous decision to reject the treatment, which was originally priced at $575,000 annually, or $39,000 per vial.
After triumphing in a four-year battle to get Chiasma's acromegaly pill across the FDA finish line last June, William Ludlam, M.D., Ph.D., is leaving to join Recordati Rare Diseases as chief medical officer.